Codexis Stock

Codexis EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Codexis (CDXS) as of Jul 20, 2026 is -1.86. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -1.98 — a change of -6.09% (higher).

EV/EBIT

-1.86

YoY

-6.09%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Codexis is 2026 -1.86 . EV/EBIT (Enterprise Value to EBIT) of Codexis was 2025 -1.98 . It decreases by -6.09% higher compared to the previous year.

The Codexis EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
-72.27 base
Jan 1, 2020
-54.26 base
Jan 1, 2021
-88.99 base
Jan 1, 2022
-9.60 base
Jan 1, 2023
-3.79 base
Jan 1, 2024
-6.00 base
Jan 1, 2025 (e)
-2.11 base
Jan 1, 2026 (e)
-4.23 base
YEARPRICE-TO-EBIT
2026 est -4.23
2025 est -2.11
2024 -6.00
2023 -3.79
2022 -9.60
2021 -88.99
2020 -54.26
2019 -72.27
2018 -77.15
2017 -16.77
2016 -21.72
2015 -21.37
2014 -5.04
2013 -1.33
2012 -2.96
2011 -11.90
2010 -36.73
2009 -
2008 -
2007 -
2006 -
2005 -
Access this data via the Eulerpool API

Codexis Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Codexis's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Codexis's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Codexis's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Codexis grows earnings faster than its peers.

Codexis Stock analysis

What does Codexis do? Codexis Inc. is an American biotechnology company that specializes in developing innovative biological solutions for a variety of industries. The company was founded in 2002 and is headquartered in Redwood City, California. Business Model: Codexis is service-oriented and provides customized enzyme solutions for companies looking to improve their products through sustainable processes. The company has developed a unique platform called Rational Protein Engineering, which allows for the development of specific enzymes for various industries. Customers benefit from enzyme optimization expertise and know-how. Divisions: Codexis operates in the fields of life sciences, materials science, agrochemicals, and biofuels. 1. Life Sciences: Codexis specializes in the production of enzymes and biocatalysts for the pharmaceutical industry in the life sciences division. The goal is to provide a faster and more efficient manufacturing process for pharmaceutical active ingredients. The company has successfully developed active ingredients for antibodies, lipids, uric acid, and antivirals. 2. Materials Science: In the materials science division, Codexis specializes in the production of enzymes for materials such as dyes, polymers, and cosmetic products. Codexis ensures that these products are efficiently manufactured without the use of environmentally harmful chemicals. 3. Agrochemicals: Codexis offers customized enzyme solutions to agrochemical manufacturers that reduce the use of chemicals and benefit the environment. These enzymes help in the production of pesticides and other agrochemicals. 4. Biofuels: In the biofuels division, Codexis specializes in the production of enzymes for processing corn, harvested plants, or waste products. These enzymes help enable cost-effective biofuel production. Products: Codexis has developed a wide range of products tailored to the needs of various industries. Some of the products recently introduced to the market by Codexis include: 1. CodeEvolver: CodeEvolver is a platform that allows biotechnology companies to quickly create customized enzyme solutions for their specific needs. The process is fully automated and results in a significant reduction in development time and costs. 2. Codex® screening panels: Codexis offers various screening panels that allow customers to quickly and efficiently select the enzymes best suited for their purposes. The panels are suitable for industries including pharmaceuticals, chemicals, and plant protection. 3. Codex® enzymes: Codexis offers a wide range of enzymes specifically designed for different industry needs. This includes enzymes for the production of biofuels, pesticides, cosmetic products, and pharmaceuticals. Overall, Codexis Inc. has demonstrated its ability to deepen the understanding of biocatalysts and introduce innovative biological processes in a variety of industries through its unique Rational Protein Engineering platform. Codexis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Codexis stock

EV/EBIT (Enterprise Value to EBIT) of Codexis is -1.86 in 2026.

Access this data via the Eulerpool API

Valuation — Codexis

All Key Metrics — Codexis